Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices.
Bioanalysis
; 8(20): 2125-34, 2016 Oct.
Article
em En
| MEDLINE
| ID: mdl-27611731
ABSTRACT
AIM:
The non-nucleoside reverse transcriptase inhibitor efavirenz is one of the most prescribed antiretroviral therapeutics. Efavirenz-containing therapy has become associated with the occurrence of CNS side effects, including sleep disturbances, depression and even psychosis.RESULTS:
The investigation of efavirenz distribution required the development of a versatile and sensitive method. In addition to plasma, quantification was required in brain tissue and phosphate-buffered saline. The assay presented here was linear from 1.9 to 500 ng/ml. Accuracy and precision ranged between 93.7 and 99.5%, and 1.5 and 5.6%, respectively.DISCUSSION:
The method developed here represents a versatile, sensitive and easy-to-use assay. The assay has been applied to in vitro and in vivo samples demonstrating reliable efavirenz quantification in multiple matrices.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Cromatografia Líquida de Alta Pressão
/
Inibidores da Transcriptase Reversa
/
Testes de Química Clínica
/
Benzoxazinas
/
Espectrometria de Massas em Tandem
Limite:
Animals
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article